Stryker has announced that it has completed the acquisition of Nico Corporation—a company attempting to provide a systematic approach to minimally invasive surgery for tumour and intracerebral haemorrhage (ICH) procedures.
As noted in a recent company press release, this acquisition further strengthens Stryker’s commitment to neurotechnology through tumour and stroke care.
The release adds that Nico’s BrainPath and Myriad products enable a treatment option for ICH—a deadly form of stroke associated with high morbidity and a 30-day mortality rate ranging from 40–50%—that provides improved functional outcomes compared to guideline-based medical management alone, the current standard of care.
“The acquisition of Nico Corporation expands Stryker’s portfolio of solutions for tumour resection and the treatment of ICH, the deadliest form of stroke,” said Andy Pierce, group president, MedSurg and Neurotechnology, Stryker. “As a global leader in neurosurgical access and removal tools, this strategic addition enables us to deliver differentiated, minimally invasive approaches that will drive meaningful outcomes and improve the lives of patients worldwide.”
